Stock Market Today, March: CytomX Surges on Positive Data
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Using historical data can significantly enhance your ability to choose index funds. Learn how to leverage this information for better investments.
26,191 articlesCytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
A quiet revolution is unfolding in AI infrastructure. This article explains why the stock market underestimating mass...
March 2026 brings a wave of Koyfin alternatives as traders seek deeper data, faster alerts, and cleaner interfaces. H...
A fresh look at an internal code snippet raises questions about Anthropic’s plans for Fable 5, potentially tying week...
Marvell faces a pivotal year as data centers, 5G networks, and AI workloads shape demand. This guide breaks down what...
Qualcomm is pivoting from phones to AI chips and software, aiming to blend edge intelligence with data-center power. ...
Revolution Medicines has surged in 2026, with revolution medicines nearly 140% year-to-date gains drawing investor at...
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Palantir and CoreWeave are at the center of the AI investment wave. This guide breaks down which is better for your p...
As the AI era expands, investors are eyeing a broader landscape beyond Nvidia. This article explores a rising AI infr...
NVIDIA has slipped about 17% from its May high, leaving investors debating whether the AI powerhouse is finally a bar...